Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

Summary

This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary concurrent chemo-radiotherapy (CRT), comparing overall survival (OS) time in subjects treated with tecemotide versus subjects treated with tecemotide-matching placebo.

Timeline

Start

2014-03

Primary completion

2015-07

Completion

2015-07

Drugs

Indications